Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Crohn Disease 3Lymphoma, Follicular 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Certolizumab Pegol × Clear all
NCT03357471 2019-10-25

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

UCB Pharma

Phase 3 Completed
70 enrolled 16 charts
Lymphoid

Lymphoma, Follicular

NCT00552058 2018-08-09

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

UCB Pharma

Phase 3 Completed
439 enrolled 25 charts

Crohn Disease

NCT00333788 2018-08-07

Welcome2

UCB Pharma

Phase 3 Completed
233 enrolled 31 charts

Crohn Disease

NCT00297648 2011-08-31

MUSIC

UCB Pharma

Phase 3 Completed
89 enrolled 43 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡